EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Haemonetics's enterprise value is $5,055 Mil.
Haemonetics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $264 Mil. Therefore, Haemonetics's EV-to-EBITDA for today is 19.18.
The historical rank and industry rank for Haemonetics's EV-to-EBITDA or its related term are showing as below:
HAE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.33 Med: 22.05 Max: 63.56
Current: 19.18
During the past 13 years, the highest EV-to-EBITDA of Haemonetics was 63.56. The lowest was 13.33. And the median was 22.05.
HAE's EV-to-EBITDA is ranked worse than 60.33% of 489
companies
in the Medical Devices & Instruments industry
Industry Median: 15.23
vs HAE: 19.18
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Haemonetics EV-to-EBITDA Historical Data
The historical data trend for Haemonetics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Haemonetics's EV-to-EBITDA
For the Medical Instruments & Supplies subindustry, Haemonetics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haemonetics's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Haemonetics's EV-to-EBITDA falls into.
Haemonetics EV-to-EBITDA Calculation
Haemonetics's EV-to-EBITDA for today is calculated as:
Haemonetics's current Enterprise Value is $5,055 Mil.
Haemonetics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $264 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haemonetics (NYSE:HAE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Haemonetics's PE Ratio for today is calculated as:
Haemonetics's share price for today is $87.66.
Haemonetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Haemonetics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HAE has been successfully added to your 